Navigation Links
Human Genome Sciences Announces Positive Results in Second of Two Phase 3 Trials of Albuferon(R) in Chronic Hepatitis C
Date:3/9/2009

9 days. Research has shown that genetic fusion of therapeutic proteins to human albumin decreases clearance and prolongs the half-life of the therapeutic proteins.

Albuferon is being developed by HGS and Novartis for the treatment of chronic hepatitis C under an exclusive worldwide co-development and commercialization agreement entered into in June 2006. HGS and Novartis will co-commercialize Albuferon in the United States and will share clinical development costs, U.S. commercialization costs and U.S. profits equally. Novartis will be responsible for commercialization in the rest of the world and will pay HGS a royalty on those sales. Clinical development, commercial milestone and other payments to HGS could total as much as $507.5 million, including $132.5 million received to date.

About Hepatitis C

Hepatitis C is an inflammation of the liver caused by the hepatitis C virus. It is estimated that as many as 170 million people worldwide are infected with hepatitis C virus. This includes nearly four million people in the United States. When detectable levels of HCV persist in the blood for at least six months, a person is diagnosed with chronic hepatitis C. Hepatitis C virus can cause serious liver disease, leading to cirrhosis, primary liver cancer and even death. Patients infected with the genotype 1 hepatitis C virus account for approximately 75% of the chronic hepatitis C patients in the U.S.

Conference Call

HGS management will hold a conference call to discuss this announcement today at 8:15 AM Eastern. Investors may listen to the call by dialing 888-203-1112 or 719-457-0820, passcode 4076361, five to 10 minutes before the start of the call. A replay of the conference call will be available within a few hours after the call ends. Investors may listen to the replay by dialing 888-203-1112 or 719-457-0820, confirmation code 4076361. A replay of the conf
'/>"/>

SOURCE Human Genome Sciences, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. Drug Development Program Started Based on CAP(R) Human Cell Line
2. Human Genome Sciences Announces Fourth-Quarter and Full-Year 2008 Financial Results and Key Developments
3. IlluminOss Medical Announces First Human Case Utilizing a Unique, New, Minimally Invasive Technology for Fracture Repair is Performed at Medical Hospital del Trabajadar in Santiago, Chile
4. GeoVax Starts Injections for Phase 2a Human HIV/AIDS Vaccine Trial in USA
5. FDA Grants Priority Review of a Supplemental Biologics License Application for Cinryze(TM) C1 Inhibitor (Human) as Treatment for Acute Attacks of Hereditary Angioedema (HAE)
6. Cloned Human Embryos Successfully Reprogrammed Using Human - But Not Animal - Eggs
7. Human Genome Sciences Begins Delivery of First-in-Class Anthrax Treatment to U.S. Strategic National Stockpile
8. Mardil Inc. Advances Its Novel Cardiac Device to First-In-Human Trials for Mitral Valve Regurgitation
9. Modigene Announces Positive Results of Pilot Toxicity Study of Its Long-Acting Human Growth Hormone hGH-CTP
10. Human Genome Sciences Reports Substantial Progress Toward Commercialization and Announces 2009 Goals at JPMorgan Healthcare Conference
11. Cequent to Present First Proof of Activity of an Oral RNAi Drug in Non-Human Primates at February Keystone Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... YORK , Dec. 17, 2014 ... imaging (MRI), the MRI market is seeing new ... and breast MRI scans account for the majority ... a higher resolution of images, which are creating opportunities ... imaging (MRI) market is growing at a rate ...
(Date:12/17/2014)... -- , The new Dompé ... information concerning the biopharmaceutical Group,s national and international clinical research ... the recently launched institutional website that is receiving accolades from ... a new chapter in the fascinating story of Drug Discovery ... panoramic hub on the world of clinical research, ranging from ...
(Date:12/17/2014)... BUENA, N.J. , Dec. 17, 2014  IGI ... announced today the closing of its offering of $125 ... due 2019 (the "Notes").  The Notes were offered and ... 144A under the Securities Act of 1933, as amended ... at a fixed rate of 3.75% per year, payable ...
Breaking Medicine Technology:Kalorama: 3T Advancements Bringing New Growth to the MRI Market 2Kalorama: 3T Advancements Bringing New Growth to the MRI Market 3Dompé Offers a New "Window" on the World of Scientific Research, with the http://www.dompetrials.com Website, Dedicated to Clinical Trials 2Dompé Offers a New "Window" on the World of Scientific Research, with the http://www.dompetrials.com Website, Dedicated to Clinical Trials 3IGI Laboratories Announces Closing of $125 Million of 3.75% Convertible Senior Notes Due 2019 2IGI Laboratories Announces Closing of $125 Million of 3.75% Convertible Senior Notes Due 2019 3IGI Laboratories Announces Closing of $125 Million of 3.75% Convertible Senior Notes Due 2019 4
... , Rochester Medical Corporation (Nasdaq: ROCM ) will ... 2009. The Company will then hold a quarterly conference call ... 3:30 p.m. central time (4:30 p.m. eastern time). , This call ... Medical,s website at www.rocm.com . To listen ...
... Oct. 28 Qualsec (OTC Bulletin Board: QLSZ), which recently ... has been elected as a member of the Board of ... of clinical experience followed by 6 years of medical device ... and only FDA cleared RFID medical information device of its ...
Cached Medicine Technology:Rochester Medical Announces Fourth Quarter 2009 Earnings Conference Call Thursday, November 5th 2009 2VitaminSpice Appoints Dr. Richard F. Seelig as Director 2
(Date:12/17/2014)... HealthDay Reporter TUESDAY, Dec. ... fast approaching, a new study reveals that states that routinely ... drunk drivers on their roads. The finding suggests that ... able to deter inebriated revelers from getting behind the wheel ... being passed regarding drinking and driving," said study lead author ...
(Date:12/15/2014)... Cancer researchers have just published an ... of deadly malignant pleural mesothelioma. Surviving Mesothelioma has just ... Click here to read it now. , ... Center, and New York’s Langone Medical Center performed complete ... in an effort to pinpoint the genes that ...
(Date:12/15/2014)... SIMpalm, a leading mobile app development company , ... client, which allows users to keep track of wines ... the right wine. At the center of WineMatch ... and wine information. All this information is assembled to ... that are close counterparts to one another are called ...
(Date:12/15/2014)... SUNDAY, Dec. 14, 2014 (HealthDay News) -- Expert pilots ... which explains why they make better decisions during landings, ... the most difficult techniques for pilots to master, and ... of fatal crashes occur during final approach and landing. ... pilots and 12 moderately experienced pilots while they were ...
(Date:12/15/2014)... 15, 2014 In support of ... attention to restrictive state laws that may have ... this important area of public health policy. , ... the Integrity of Independent Review, contends that state ... independent peer review determinations can result in subpar ...
Breaking Medicine News(10 mins):Health News:Enforcement of Drunk Driving Laws Makes Roads Safer, Study Finds 2Health News:Enforcement of Drunk Driving Laws Makes Roads Safer, Study Finds 3Health News:New Study Reveals Genetic Mutations That May Trigger Mesothelioma, According to Surviving Mesothelioma 2Health News:Use WinMatch Connect App to Keep Track of Wines You Like 2Health News:Study Shows Why Expert Pilots Are Experts 2Health News:NAIRO Calls for Higher Quality Independent Peer Review By Ending Restrictive State Laws 2
... geared to genetic blueprints from Elite Books, TUCSON, Ariz., ... It,plays a key role in the development of Alzheimer,s Disease ... it is greatly affected,by diet. In her seminal book, ... Heart and Alzheimer,s Using the Body,s Own Genes,(Elite, Hardcover, $27.95, ...
... FRAMINGHAM, Mass., Nov. 5 StatSure Diagnostic,Systems, Inc. ... U.S.,Food and Drug Administration ("FDA"), through its Center ... under the Clinical Laboratory,Improvements Amendments of 1988 ("CLIA") ... patented "barrel" technology. The HIV 1/2 product,is marketed ...
... to place systems in more physician offices could ... of underserved patient populations, NEW YORK, Nov. 5 ... New York (HIP) will convene an educational seminar in,New ... treating,underserved patient populations. The seminar, to be held at ...
... Research Findings to Impact Human Health, Agricultural Science, ... Beauty announced that they successfully sequenced the complete ... fungus,responsible for the onset of dandruff and other ... are published in today,s online edition of,Proceedings of ...
... 5 Millennium,Pharmaceuticals, Inc. (Nasdaq: MLNM ) ... Suisse Healthcare Conference will be webcast live and,may ... the Company,s website, http://www.millennium.com . (Logo: ... an overview of the Company, an update on,clinical ...
... to Compulsory Acquisition, WARSAW, Ind. and MONTREAL, Nov. ... ZMH), a leader in the orthopaedics,industry, and its indirect ... pursuant to the extension of the Offer,made for all ... a leader in computer navigation for orthopaedic,surgery, it has ...
Cached Medicine News:Health News:Groundbreaking Apo E Gene Diet Linked to Alzheimer's Disease and Heart Disease Prevention 2Health News:StatSure's Patented HIV 'Barrel' Technology Receives CLIA Waiver From FDA 2Health News:StatSure's Patented HIV 'Barrel' Technology Receives CLIA Waiver From FDA 3Health News:GHI and HIP Lead Effort to Expand Electronic Health Record System Throughout the City of New York 2Health News:Photo: Scientists Complete Genome Sequence of Fungus Responsible for Dandruff, Skin Disorders 2Health News:Photo: Scientists Complete Genome Sequence of Fungus Responsible for Dandruff, Skin Disorders 3Health News:2007 Credit Suisse Healthcare Conference to Webcast Millennium Presentation 2Health News:Zimmer Announces Successful Completion of ORTHOsoft Takeover Bid 2Health News:Zimmer Announces Successful Completion of ORTHOsoft Takeover Bid 3
3 mm diameter roller blade, 15 mm from angle to tip. Round handle....
2 mm wide x 3 mm long, with rounded triangular tip. Angled 45 degrees. Hexagonal handle....
Duckbill type sharp. 3 mm wide x 8 mm long curved blade. Octagonal handle....
9 mm slightly curved blade. Hexagonal handle....
Medicine Products: